PDF | Background: The outbreak of coronavirus disease 2019 (COVID-19) posed an enormous threat to public health
The Kaletra group demonstrated that they have improved clinical scores, and for some a lower mean viral load in the lungs
Materials & methods: Data from randomized and observational studies were included in meta-analyses
F
Other supportive measures such as acetaminophen, prophylactic anticoagulant, hydration, and oxygen therapy were prescribed based on the patient's clinical condition
Methods: We conducted a phase III multicentre, open
Large clinical trials have demonstrated lopinavir/ritonavir’s clinical efficacy in both antiretroviral-naïve and -experienced patients
Interferon-β1b and lopinavir–ritonavir reduced mortality in patients with lower IL-2, IL-8 and IL-13 plasma concentrations but not in patients with higher levels (p-value for interaction = 0
Chinese Medical Journal
The effect Other exclusion criteria include using drugs with potential interaction with Hydroxychloroquine + Lopinavir/Ritonavir, Interferon-β 1a, Interferon-β 1b, pregnant or lactating women, history of alcohol or drug addiction in the past 5 years, blood ALT/AST levels > 5 times the upper limit of normal on laboratory results and refusal to participate
Many of the studies that evaluated the use of systemic interferons for the treatment of hospitalized adults with COVID-19 were conducted in early 2020, before the widespread use of remdesivir or corticosteroids and other immunomodulators
Here, we show that remdesivir (RDV) and IFNb have superior antiviral activity to LPV and RTV in vitro